Seer to Participate in Upcoming November Investor Conferences
Seer (Nasdaq: SEER) has announced its participation in two upcoming investor conferences in November.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer (Nasdaq: SEER) has announced its participation in two upcoming investor conferences in November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 11th at 11:30 a.m. ET, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21st at 10:00 a.m. ET.
Both sessions will be available via live webcast on the Investor section of Seer's website at investor.seer.bio, with archived replays accessible after the events.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was +7.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences:
- Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA
Fireside chat on Monday, November 11th at 11:30 a.m. Eastern Time - Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY
Fireside chat on Thursday, November 21st at 10:00 a.m. Eastern Time
Live webcasts of the sessions will be available on the Investor section of Seer’s website at investor.seer.bio. Archived replays will be available on the company’s website following the conference.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.